The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 25, 2023 for Kambam Kirthi Reddy

This has reference to our letter dated December 20, 2022, wherein we intimated about the initiation of the Postal Ballot process seeking approval of the Members by way of special resolution for re-appoint Mr. Girish Paman Vanvari (DIN:07376482) as an Independent Director of the Company for the second term of five consecutive years from November 5, 2022, to November 4, 2027. In this regard, please find enclosed voting results of the Postal Ballot, as required under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer''s Report.

This is to inform that the officials of the Company will be participating in the following investor meeting: Date Time Name of the Investor Type of meeting 19-01-2023 7:30 AM Matthews Asia Virtual No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The United States Food and Drug Administration (US FDA) inspected the Company's wholly owned subsidiary, APL Health Care Limited's Unit I & III, an Orals (Tablets, Capsules and Soft gel Capsules) and Derma Manufacturing facility located at Jadcherla, Mahabub Nagar District, Telangana, from January 9 to January 18, 2023. At the end of the inspection, we have been issued a 'Form 483' with 2 observations. The observations are procedural in nature. We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observations at the earliest.

This is to certify that the details of securities dematerialized/rematerialized during the quarter ended December 31, 2022, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished to all the stock exchanges where the shares of the Company are listed. The letter confirming this from our RTA - M/s. KFin Technologies Limited dated January 5, 2023 is enclosed for your reference. Further, the certificates of securities which were dematerialized, are listed on the Stock Exchanges where earlier issued securities of the Company were listed.

This is to inform that the officials of the Company will be participating in the following investor meetings: Date Time Name of the Investor Type of meeting 09-01-2023 8:30 PM Barrow Hanley Global Investors Virtual 09-01-2023 9:30 PM Oaktree Capital Management, L.P. Virtual 09-01-2023 10:30 PM TCW Asset Management Company Virtual 11-01-2023 8:30 PM BlackRock, Inc. Virtual

We enclose a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company, for Azacitidine for Injection.

This is to inform that as per the Company's Internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in the securities of the Company would remain closed for all designated persons including Promoters, Directors, Key Managerial Personnel, Employees, Connected Persons and their immediate relatives with effect from January 1, 2023 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ending on December 31, 2022. The date of the Board Meeting for declaration of the Financial Results of the Company for the third quarter and nine months period ending on December 31, 2022, will be intimated in due course.